Beta‐blockers in patients with cirrhosis and refractory ascites
Albillos Agustín, Zamora Javier – 11 October 2010
Effect of sorafenib on murine liver regeneration
Caroline Hora, Pamela Romanque, Jean‐François F. Dufour – 11 October 2010 – Hepatocellular carcinoma (HCC) is a common cause of cancer‐related death. Sorafenib prolongs survival of patients with advanced disease and is approved for the systemic treatment of unresectable HCC. It possesses antiangiogenic and antiproliferative properties by way of inhibition of the receptor tyrosine kinases vascular endothelial growth factor receptor 2 (VEGFR‐2) and platelet‐derived growth factor receptor‐beta 1/2 (PDGFR‐β) and the kinase RAF.
Reply
See Ching Chan, Chung Mau Lo, Sheung Tat Fan – 11 October 2010
Apoptotic cells attenuate fulminant hepatitis by priming Kupffer cells to produce interleukin‐10 through membrane‐bound TGF‐β
Minggang Zhang, Sheng Xu, Yanmei Han, Xuetao Cao – 6 October 2010 – The liver, a unique tolerogenic organ, is regarded as the site to trap and destroy aging erythrocytes and activated T cells. However, to date, the mechanisms for why the liver is tolerogenic and whether liver Kupffer cells (KC) are critical phagocytes for apoptotic cells (AC) contributing to the liver immunosuppression remain unclear. Here we report that KC is the main phagocyte for AC in the liver.
Is achievement of sustained virologic response an independent predictor or a cofactor for the development of esophageal varices?
Li‐Ping Ye, Xin‐Li Mao – 6 October 2010
Proceed with caution: Peginterferon alpha‐2a versus peginterferon alfa‐2b in chronic hepatitis C. A systematic review of randomized trials
David Kershenobich, Linda Muñoz, René Malé, Jesús Gaytan, Francisco Sánchez – 6 October 2010
Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection
Jennifer R. Kramer, Christine Y. Hachem, Fasiha Kanwal, Minghua Mei, Hashem B. El‐Serag – 6 October 2010 – Coinfection with hepatitis A virus (HAV) or hepatitis B virus (HBV) in patients with chronic hepatitis C virus (HCV) is associated with increased morbidity and mortality. The Center for Medicare and Medicaid Services has identified HAV and HBV vaccination as a priority area for quality measurement in HCV. It is unclear to what extent patients with HCV meet these recommendations.
Working with a gold‐plated standard
Terry Therneau – 6 October 2010
Necrosis versus apoptosis in acetaminophen‐induced hepatotoxicity
Klaus Schulze‐ Osthoff, Heike Bantel – 6 October 2010
CXC chemokine receptor‐1 is expressed by hepatocytes and regulates liver recovery after hepatic ischemia/reperfusion injury
Callisia Clarke, Satoshi Kuboki, Nozomu Sakai, Kevin R. Kasten, Amit D. Tevar, Rebecca Schuster, John Blanchard, Charles C. Caldwell, Michael J. Edwards, Alex B. Lentsch – 6 October 2010 – CXC chemokines mediate hepatic inflammation and injury following ischemia/reperfusion (I/R). More recently, signaling through CXC chemokine receptor‐2 (CXCR2) was shown to delay liver recovery and repair after I/R injury. The chemokine receptor CXCR1 shares ligands with CXCR2, yet nothing is known about its potential role in liver pathology.